RxDoctor Payments Data

Thomas Ziering, MD

Family Medicine · Morristown, NJNPI 1902854870

Payments from drug & device makers

$1,190in general payments, 2019–2025

Across 96 payments — averaging $12.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$360
  • AbbVie$179
  • Arbor Pharmaceuticals, Inc.$167
  • Viiv Healthcare Company$136
  • Lilly USA, LLC$76
  • Gilead$70
  • plus $202 from 10 others

What the payments were for

  • Food & beverage$1,190100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,190 in reported general payments places this provider in the 70th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$50,812
Medicare patients
73
Services billed
567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$61,466
BiktarvyBictegrav/Emtricit/Tenofov Ala12$55,369
MounjaroTirzepatide26$45,443
TrulicityDulaglutide21$42,421
JardianceEmpagliflozin19$26,083
MyrbetriqMirabegron13$7,274
EdarbiAzilsartan Medoxomil16$6,251
Nebivolol Hcl26$2,089
Rosuvastatin Calcium90$2,039
Humalog Kwikpen U-100Insulin Lispro12$1,584
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$692
Valsartan16$608
Albuterol Sulfate HfaAlbuterol Sulfate16$604
Ezetimibe24$596
Levothyroxine Sodium54$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$76$87,86447 claims
Novo NordiskOzempic$360$61,46637 claims
GileadBiktarvy$70$55,36912 claims
Arbor Pharmaceuticals, Inc.Edarbi$167$6,25116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →